- In November 2024, Recursion and Exscientia completed their business combination, with Exscientia now a wholly owned subsidiary of Recursion, forming a vertically-integrated AI-powered drug discovery platform. Exscientia's ADSs will be delisted from Nasdaq. This merger will enhance the companies' ability to streamline and accelerate drug discovery through advanced technology and integrated capabilities.
- In September 2024, Gilead Sciences and Genesis Therapeutics formed a strategic collaboration to discover and develop novel small molecule therapies using the GEMS AI platform. The partnership will focus on generating and optimizing molecules for multiple targets. This collaboration will enhance the companies' ability to accelerate drug discovery and improve the efficiency of developing new therapies
- In September 2024, Insilico Medicine partnered with Inimmune to utilize its proprietary AI technology, Chemistry42, aiming to accelerate the discovery and development of next-generation immunotherapeutics. This collaboration will enhance Insilico's capabilities in designing and optimizing novel immunotherapies, potentially leading to more effective treatments for various diseases
- In July 2024, Exscientia plc expanded its collaboration with Amazon Web Services (AWS) to utilize AWS's artificial intelligence (AI) and machine learning (ML) services, enhancing its end-to-end drug discovery and automation platform. This integration will enable Exscientia to accelerate the design, synthesis, and testing of drug candidates, thereby reducing development timelines and costs
- In May 2024, Sanofi, Formation Bio, and OpenAI are partnering to create AI-powered software that will streamline drug development and accelerate the delivery of new medicines. By combining data, software, and tailored models, the collaboration aims to improve efficiency across the entire drug development process. This partnership will help the companies enhance their drug discovery capabilities, reducing time-to-market for new treatments
